Cartesian Therapeutics Inc expected to post a loss of 4 cents a share - Earnings Preview

Cartesian Therapeutics

27/02/2024 16:05

* Cartesian Therapeutics Inc  RNAC.OQ   RNAC.O  is expected
to show a fall in quarterly revenue when it reports  results on
February 29 (estimated) for the period ending December 31 2023
    * The Watertown Massachusetts-based  company is expected to
report
a 65.0% decrease in revenue to $5.875 million from $16.8 million
a year ago, according to the mean estimate from 2 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Cartesian Therapeutics
Inc is
for a loss of 4 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Cartesian
Therapeutics Inc is $3.50​, above​ its last closing price
of $0.75. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.04       -0.06      -0.06     Met     -2.9
 Jun. 30 2023  -0.08       -0.08      -0.07     Beat    12.5
 Mar. 31 2023  -0.09       -0.09      -0.14     Missed  -60.7​
 Dec. 31 2022  -0.08       -0.07      0.04      Beat    154.9
 ​​Sep.        0.03        -0.01      -0.05     Missed  -775.7
 30 2022                                                
 Jun. 30 2022  -0.06       -0.08      0.06      Beat    177.8​
 Mar. 31 2022  -0.10       -0.11      0.23      Beat    312.3
 Dec. 31 2021  -0.08       -0.07      0.03      Beat    141.2
 This summary was machine generated February 27 at 16:05 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)